We use cookies to understand how you use our site and to improve the overall user experience. This includes personalizing content and advertising. Read our Privacy Policy
Accept Cookies
In patients with acute myeloid leukemia (AML), treatment stratification is largely based on pretreatment factors, including cytogenetic and molecular aberrations and measurable/minimal residual disease (MRD) during treatment. Sequential MRD monitoring allows assessment of response to chemotherapy and early detection of relapse, potentially identifying patients in need of preemptive or more intensive therapy.
We use cookies to understand how you use our site and to improve the overall user experience. This includes personalizing content and advertising. Read our Privacy Policy